following an abbreviated submission
beclometasone dipropionate and formoterol fumarate dihydrate metered dose inhaler 100microgram / 6microgram (Fostair®) is accepted for use within NHS Scotland.
Indication under review: Symptomatic treatment of patients with severe COPD (FEV1 <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.
Fostair® should be used in patients for whom beclometasone and formoterol are appropriate choices of corticosteroid and long-acting beta2-agonist respectively, and for whom a metered dose inhaler is an appropriate delivery device.
The introduction of Fostair® is likely to be cost neutral. The 100mcg dose of beclometasone in Fostair® is not bioequivalent to a 100mcg dose of beclometasone in several other inhaler formulations.
Download detailed advice110KB (PDF)
Medicine details
- Medicine name:
- beclometasone dipropionate / formoterol fumarate dihydrate (Fostair)
- SMC ID:
- 976/14
- Indication:
- Symptomatic treatment of patients with severe COPD (FEV1 <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.
- Pharmaceutical company
- Chiesi Limited
- BNF chapter
- Respiratory system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 07 July 2014